Therefore, we conclude that the pharmacological inhibition of MAPK signaling in undifferentiated thyroid cancer cells carrying a BRAF or Ras mutation induces p38 phosphorylation, which subsequently activates CREB and leads to L-GILZ transcriptional activation. Here, TSC22D3 is linked to thyroid gland carcinoma.